Nanjing Well Pharmaceutical GroupLtd Balance Sheet Health
Financial Health criteria checks 5/6
Nanjing Well Pharmaceutical GroupLtd has a total shareholder equity of CN¥1.7B and total debt of CN¥423.9M, which brings its debt-to-equity ratio to 25.3%. Its total assets and total liabilities are CN¥2.3B and CN¥603.6M respectively. Nanjing Well Pharmaceutical GroupLtd's EBIT is CN¥166.9M making its interest coverage ratio 12. It has cash and short-term investments of CN¥169.9M.
Key information
25.3%
Debt to equity ratio
CN¥423.87m
Debt
| Interest coverage ratio | 12x |
| Cash | CN¥169.87m |
| Equity | CN¥1.68b |
| Total liabilities | CN¥603.60m |
| Total assets | CN¥2.28b |
Recent financial health updates
No updates
Recent updates
Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Earnings Are Of Questionable Quality
Aug 26
Nanjing Well Pharmaceutical GroupLtd's (SHSE:603351) Upcoming Dividend Will Be Larger Than Last Year's
Jun 07Little Excitement Around Nanjing Well Pharmaceutical Group Co.,Ltd.'s (SHSE:603351) Earnings
Jun 06Financial Position Analysis
Short Term Liabilities: 603351's short term assets (CN¥599.2M) exceed its short term liabilities (CN¥516.1M).
Long Term Liabilities: 603351's short term assets (CN¥599.2M) exceed its long term liabilities (CN¥87.5M).
Debt to Equity History and Analysis
Debt Level: 603351's net debt to equity ratio (15.2%) is considered satisfactory.
Reducing Debt: 603351's debt to equity ratio has increased from 8.4% to 25.3% over the past 5 years.
Debt Coverage: 603351's debt is well covered by operating cash flow (53.3%).
Interest Coverage: 603351's interest payments on its debt are well covered by EBIT (12x coverage).